Abstract
Elderly and poor performance status advanced non-small-cell lung cancer (NSCLC) patients often tolerate chemotherapy poorly. Special approaches are needed for these patient populations. Gefitinib (Iressa) was used in 59 elderly and/or unfit NSCLC pretreated patients participating in a compassionate use programme showing some activity and good tolerability.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Female
-
Frail Elderly*
-
Gefitinib
-
Health Status
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / pathology
-
Male
-
Middle Aged
-
Quinazolines / adverse effects
-
Quinazolines / pharmacology
-
Quinazolines / therapeutic use*
Substances
-
Antineoplastic Agents
-
Quinazolines
-
Gefitinib